NCT06991296View on ClinicalTrials.gov

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

NARecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Obesity
Interventions
DIETARY_SUPPLEMENT

SPM Active®

Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).

Trial Locations (1)

28081

RECRUITING

UNC Nutrition Research Institute, Kannapolis

Sponsors

Collaborators (1)

Metagenics, Inc.
All Listed Sponsors
collaborator

Metagenics, Inc.

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT06991296 - Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation. | Biotech Hunter | Biotech Hunter